Author

Kum Kum Khanna

Translational Research InstituteORCID 0000-0001-8650-5381Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Kum Kum Khanna1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

Amanda Louise BainiD· 1 shared Antonella PapaiD· 1 shared Asmerom Tesfamariam SengaliD· 1 shared B. Bowden· 1 shared Behnam RashidiehiD· 1 shared Ben B. Wang· 1 shared Catharina Vosloo· 1 shared George R. AmbalathingaliD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Amanda Louise BainORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyAdvanced SciencePeer-reviewedAug 10, 2026

Genetic Ablation and Multi-Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models

Behnam Rashidieh, Yuanhao Yang, Amanda Louise Bain…·Kum Kum Khanna

This study shows that CEP55 promotes tumorigenesis in cancer models and its deletion suppresses tumor growth and improves survival, especially in PTEN-deficient cancers.

DOI 10.1002/advs.76782

mouseproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMar 16, 2025

Thioredoxin reductase 3 inhibition sensitizes triple-negative breast cancer cells to EGFR inhibitors

Prahlad V. Raninga, Göknur Giner, Sivanandhini Sankarasubramanian…·Kum Kum Khanna

This study identifies TXNRD3 as a target to sensitize triple-negative breast cancer cells to EGFR inhibitors by enhancing EGFR activation and surface localization.

DOI 10.1101/2025.03.16.642742

humanproteomics

𝕏 PostBluesky